Synairgen PLC (AIM:SNG, OTC:SYGGF) announced it has recruited all 610 people for the final stage of clinical trials evaluating SNG001 in hospitalised (Coronavirus) COVID-19 patients.
The pharma group said the SPRINTER trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries.
WATCH: Synairgen 'delighted' to get green light for US government-sponsored Phase III trials, starting soon
Once the final patients have completed the initial 35-day trial period, quality assurance and statistical analysis will be completed.
Top-line data from the trial is expected in early 2022 and, conditional upon a successful Phase 3 readout, the company is preparing for the filing of an Emergency Use Authorisation in the US for patients requiring hospitalisation due to COVID-19.
The trial has been granted Fast Track status from the US Food and Drug Administration and was classified as an Urgent Public Health study by the UK's National Institute for Health Research.
“Even with extensive vaccine programmes, in the US alone, thousands of patients a day are still being hospitalised due to serious COVID-19 symptoms,” said chief executive Richard Marsden.
“Doctors have highlighted the urgent need for more treatment options for these patients. We believe that SNG001, our investigational inhaled formulation of interferon beta, a naturally-occurring, broad-spectrum antiviral protein, could offer a compelling new treatment option.”
Shares surged 6% to 192.78p on Thursday morning.